Neumora Therapeutics, Inc. business relationships
Companies named in Neumora Therapeutics, Inc.’s 10-K filed 2026-03-30, and public companies whose annual reports name Neumora Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.2 / 10
- AI naming
- 46 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Neumora Therapeutics, Inc.’s annual report 2
“Under these two license agreements, Amgen is eligible to receive contingent consideration up to an aggregate of $ 360.0 million in commercial milestone payments per product payable in cash with a compound directed to CK1δ and up to an aggregate of $ 360.0 million in commercial milestone payments per...” SEC filing
“In September 2021, and concurrently with the Amgen License Agreements (see Note 7), the Company entered into a research collaboration agreement with Amgen (the "Amgen Collaboration Agreement") to collectively discover drug targets, biomarkers, and other insights associated with central nervous syste...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.